Stereotaxis (STXS) to Post Quarterly Earnings on Tuesday

Stereotaxis (NYSEAMERICAN:STXS) is anticipated to release its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect Stereotaxis to announce earnings of ($0.03) per share and revenue of $8.35 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Stereotaxis Trading Up 5.6%

Shares of NYSEAMERICAN:STXS opened at $1.33 on Tuesday. The stock has a fifty day simple moving average of $1.70 and a two-hundred day simple moving average of $1.93. Stereotaxis has a 12-month low of $1.24 and a 12-month high of $3.59. The stock has a market capitalization of $130.25 million, a price-to-earnings ratio of -5.54 and a beta of 1.37.

Hedge Funds Weigh In On Stereotaxis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STXS. WealthPLAN Partners LLC bought a new stake in shares of Stereotaxis in the 4th quarter worth $29,000. BNP Paribas Financial Markets lifted its holdings in shares of Stereotaxis by 106.5% during the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after purchasing an additional 5,910 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Stereotaxis during the third quarter valued at $38,000. HRT Financial LP bought a new position in shares of Stereotaxis during the fourth quarter valued at $42,000. Finally, Moneta Group Investment Advisors LLC purchased a new stake in shares of Stereotaxis during the third quarter valued at $43,000. 45.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

STXS has been the subject of several analyst reports. Piper Sandler restated an “overweight” rating and set a $3.50 price target (down from $4.00) on shares of Stereotaxis in a report on Wednesday, May 13th. Citigroup reiterated a “market outperform” rating on shares of Stereotaxis in a research note on Wednesday, June 3rd. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Stereotaxis currently has a consensus rating of “Buy” and a consensus target price of $3.88.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.